Abstract:Introduction: In patients with type 2 diabetes, increasing evidence points to pathological changes not only in the endocrine but also in the exocrine pancreas. In particular, the number of immune cells is increased in both compartments. Furthermore, patients with chronic pancreatitis, a form of exocrine inflammation, have an increased risk to develop diabetes. However, the causal relationship between exocrine pathologies and impaired endocrine insulin secretion is unknown. Methods: We established a mouse model of chronic pancreatitis using caerulein injections, thereby stimulating digestive enzymes secretion in exocrine cells. Over 3 weeks, wild-type mice underwent treatment combined with a high-fat diet to induce insulin resistance. To avoid body weight differences due to the anorexic effect of caerulein, saline-treated control mice were pair-fed. We evaluated insulin secretion and glucose metabolism by in vivo glucose tolerance testing and assessing ex vivo glucose-stimulated insulin secretion in isolated islets. Pancreata were immunohistochemically evaluated and transcriptional changes in islets were studied using RNA sequencing. Results: Chronic pancreatitis in caerulein-treated mice was confirmed by elevated immune cells in the exocrine pancreas, whereas no increase in immune cells was observed in islets. Functionally, mice with chronic pancreatitis had severely impaired insulin secretion and resulted in hyperglycemia compared to the saline-treated control mice. Islets isolated from caerulein-treated mice showed reduced glucose-stimulated insulin secretion. Surprisingly, despite exocrine tissue destruction and reduced exocrine tissue mass, β-cell mass was not reduced. Further, differentially expressed genes were not associated with β-cell signatures but with extracellular matrix components. Conclusion: Impaired insulin secretion in chronic pancreatitis may be due to alterations in the extracellular matrix components of the islets rather than to destruction of β-cells. Disclosure L. Steiger: None. D.T. Meier: None. L. Rachid: None. H. Mereau: None. M.Y. Donath: Advisory Panel; Novo Nordisk, Lilly Diabetes, Boehringer-Ingelheim. Research Support; Boehringer-Ingelheim, Olatec. A. de Baat: None. M. Boeni-Schnetzler: None. Funding Swiss National Science Foundation ( 320030_214900)

Role of GAD peptides p217 and p290 in the repair of INS receptor in salivary tissues of type 1 diabetic mice

Active Tolerance Induction and Prevention of Autoimmune Diabetes by Immunogene Therapy Using Recombinant Adenoassociated Virus Expressing Glutamic Acid Decarboxylase 65 Peptide Gad(500-585)

Glutamic Acid Decarboxylase-Derived Epitopes with Specific Domains Expand CD4(+)CD25(+) Regulatory T Cells.

Ganglioside GM1 effects on the expression of nerve growth factor (NGF), Trk-A receptor, proinflammatory cytokines and on autoimmune diabetes onset in non-obese diabetic (NOD) mice

Immunotherapy of Autoimmune Diabetes by Nasal Administration of Tandem Glutamic Acid Decarboxylase 65 Peptides

GAD-IgG-inducing CD4+Foxp3+Treg Cells Suppressing Diabetes Are Involved in the Increasing Ratio of CD80+:CD86+ Cells in NOD Mice

Autonomous sensing of the insulin peptide by an olfactory G protein-coupled receptor modulates glucose metabolism

Normal incidence of diabetes in NOD mice tolerant to glutamic acid decarboxylase

Effects of Oral Administration of Insulin and Glutamic Acid Decarboxylase on the Incidence of Diabetes Mellitus in Non-Obese Diabetic Mice

Endogenous immune response to glutamic acid decarboxylase (GAD67) in NOD mice is modulated by adjuvant immunotherapy

Vaccination of non-obese diabetic mice with a fragment of peptide P277 attenuates insulin-dependent diabetes mellitus

Plant-based vaccines for oral delivery of type 1 diabetes-related autoantigens: Evaluating oral tolerance mechanisms and disease prevention in NOD mice

Pre-clinical development of a tolerogenic peptide from glutamate decarboxylase as a candidate for antigen-specific immunotherapy in type 1 diabetes

CD4+ T cells from individuals with type 1 diabetes respond to a novel class of deamidated peptides formed in pancreatic islets

Immune and Metabolic Effects of Antigen-Specific Immunotherapy Using Multiple β-Cell Peptides in Type 1 Diabetes

Pancreatic ductal cell antigens are important in the development of invasive insulitis in Non-Obese Diabetic mice

Targeting of pancreatic glia in type 1 diabetes

Treatment with sulfatide or its precursor, galactosylceramide, prevents diabetes in NOD mice

1260-P: Gut Microbiome and Metabolic Activity in Type 1 Diabetes—An Analysis Based on the Presence of GADA

1560-P: Inflammation in the Exocrine Pancreas Impairs Insulin Secretion

1755-P: the Development of Antagonists Targeting Olfr109 to Treat Diabetes